Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

NCT00431444 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis

Interventions

DRUG: Raloxifene
DRUG: Zoledronic acid
DRUG: Placebo oral pills
DRUG: Placebo intravenous (i.v.) infusion

Sponsor

Novartis